Results · Apr-Jun 2026
Jagsonpal Pharmaceuticals Q1 FY27 results
Sales grew 9% to ₹82.2 crore from ₹75.6 crore in Apr-Jun 2025.
Operating profit grew 21% to ₹17.2 crore, an operating margin of 21.0% (up 2.2 points from a year ago).
Net profit grew 22% to ₹13.2 crore from ₹10.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +28%, net profit +51%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 82.2 | 75.6 | +9% |
| Operating profit (EBITDA) | 17.2 | 14.2 | +21% |
| Operating margin | 21.0% | 18.8% | +2.2 pts |
| Net profit | 13.2 | 10.8 | +22% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.